The Discovery Centre, AstraZeneca's research and headquarters building on the Cambridge Biomedical Campus, in January 2025 · Mr Ignavy, via Wikimedia Commons (Geograph Britain and Ireland) · CC BY-SA 2.0

Article · 2026-09-29 · 7 min read · Pharmaceuticals · Stocks

AstraZeneca puts $2 billion into Summit weeks before its FDA date

The money buys convertible preferred shares equal to about 12 percent of Summit's common stock, with no vote; Summit's own July report said its cash could not fund a year of its plans and raised substantial doubt about its future as a going concern, and it says the FDA told it a significant survival benefit is necessary for the lung-cancer approval due for a decision by 14 November, a benefit its trial did not show.

By the desk. Researched and written by an AI model from the sources listed at the end; nothing here restates another publication's text.

SMMTdirect AZNdirect BMYadjacent MRKadjacent

What AstraZeneca is paying for

On Monday 28 September Summit Therapeutics agreed to sell AstraZeneca Holdings B.V., a subsidiary of AstraZeneca, 108,955.3686 shares of a new Class A Convertible Preferred Stock for $2.0 billion, its current report says. Each preferred share converts into 1,000 common shares, so the stake converts into about 109 million common shares, a figure worked out here from the two filed numbers. AstraZeneca's own announcement says the investment gives it rights equal to about 12.0 percent of Summit's outstanding common stock, 10.6 percent on a fully diluted basis, and that closing is expected within a week. ^{[1, 3]}

The preferred shares carry no vote and take dividends only as if converted. They cannot be converted until any antitrust waiting period has run and an amendment to Summit's charter raising the number of common shares it may issue has taken effect; if that amendment is not effective within 18 months, Summit must redeem them for cash at the then-prevailing market value of the common shares behind them. The agreement also gives AstraZeneca preemptive rights and 'certain rights in the event a third party submits an acquisition proposal to the Company', and Summit must file to register the resale of the common shares within 60 days of closing. ^[1]

The two medicines

Ivonescimab blocks two proteins at once: PD-1, which tumors use to evade the immune system, and VEGF, which they use to grow blood vessels. It was engineered by Akeso, which keeps the rights in China, where it is approved for certain lung-cancer patients; Summit holds the rights in the major markets outside China, AstraZeneca's announcement says. Sonesitatug vedotin, or sone-ve, is AstraZeneca's antibody drug conjugate aimed at Claudin 18.2, a protein in the stomach lining, licensed from KYM Biosciences in March 2023; AstraZeneca reported that its CLARITY-Gastric01 trial improved overall survival in previously treated, Claudin 18.2-positive advanced gastric cancer. ^{[3, 5]}

Under the collaboration the two companies each supply their own medicine, share the costs of combined trials in gastrointestinal cancers that AstraZeneca intends to sponsor, and keep their own rights. A separate non-binding memorandum points to wider trials with more AstraZeneca cancer medicines, and Summit's release says: 'There are no additional financial considerations associated with milestones, royalties, revenue-sharing, or profit-sharing'. Summit's chairman and co-chief executive, Robert Duggan, called the investment 'a powerful validation of the potential of ivonescimab'. ^{[2, 3]}

What Summit's own report says

Summit's quarterly report for the three months to 30 June, filed on 23 July, shows $419.4 million of cash and cash equivalents and $271.3 million of short-term investments, an accumulated deficit of $2.70 billion and a net loss of $215.7 million for the quarter. It says those holdings 'are not sufficient to fund the Company's planned operations for a period of at least one year', and adds: 'These conditions raise substantial doubt about the Company's ability to continue as a going concern'. The $2.0 billion is about 2.9 times the cash and short-term investments at 30 June, a ratio worked out here from the filed figures. ^[4]

Reuters reported that Evercore ISI's analyst Cory Kasimov called the investment a validating buy-in that gives Summit a much-needed cash infusion while it keeps its strategic options, and that Barclays' James Gordon said it puts AstraZeneca on par with Bristol Myers Squibb and Merck in this class of medicine, after AstraZeneca discontinued its own bispecific, volrustomig, last month. ^[5]

The FDA's date

The same July report carries the decision that comes first. The FDA accepted Summit's application for ivonescimab with chemotherapy in advanced lung cancer with an EGFR mutation that has progressed after a third-generation EGFR-targeted drug, and set a goal date of 14 November 2026. The trial behind it, HARMONi, met its progression-free survival goal with a hazard ratio of 0.52 but did not show a statistically significant overall survival benefit, with a hazard ratio of 0.79 and a p-value of 0.057, the report says. ^[4]

In the report's own words: 'The FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting and the PFS results from this study may not be sufficient to support marketing authorization.' Summit writes that it believes the regimen offers a favorable benefit-risk profile 'despite the lack of a statistically significant OS benefit'. ^[4]

What settles it next

The closing, which the current report expects within five business days and AstraZeneca within a week; the charter amendment that must take effect before any conversion, and the 18-month deadline after which Summit would have to pay cash instead; the resale registration due within 60 days of closing; the CLARITY-Gastric01 results, which AstraZeneca says will be presented at the European Society for Medical Oncology's 2026 congress; and the FDA's action on or before 14 November. ^{[1, 3, 4]}

Who it reaches

Summit directly, as the issuer and as the company whose July report carried the going-concern doubt the money addresses; AstraZeneca directly, as the investor and trial partner; and Bristol Myers Squibb and Merck as the peers Barclays' analyst named, as Reuters reported, already holding medicines of the same class. ^{[1, 4, 3, 5]}

Sources

Every stock is a company; the desk grades the company behind the stock. This article describes; it does not recommend. Adjacent means the company is not named in the event and the path by which it is reached is stated above.

All news →